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1. Introduction
Camptocormia, which is also known as bent spine syndrome, is characterized by abnormal
posture of the trunk with marked forward flexion of the thoracolumbar spine, which increases
during standing and walking and abates in the recumbent position (Azher & Jankovic, 2005).
Camptocormia is a disabling symptom that occurs during the course of Parkinson’s disease
(PD), but the optimized medical and surgical therapy for PD-associated camptocormia remains
to be established (Finsterer & Strobl, 2010; Doherty et al., 2011). PD-associated camptocormia
is generally thought to be unresponsive to levodopa (Azher & Jankovic, 2005). In most patients
with PD, the extreme anterior bending is not or poorly improved, or even worsened, in
response to levodopa administration, and the severity of the bent spine is often unchanged
during the medication-on and -off phases (Melamed & Djaldetti, 2006), although an excep‐
tional case has been reported (Ho et al., 2007). Although some reports have shown that deep
brain stimulation (DBS) in the subthalamic nucleus (STN) (Hellmann et al., 2006; Yamada et
al., 2006; Sako et al., 2009; Umemura et al., 2010; Capelle et al., 2011; Asahi et al., 2011) and
globus pallidus internus (GPi) (Micheli et al., 2005; Capelle et al., 2011; Thani et al., 2011) is
effective in treating camptocormia, the overall efficacy of DBS in relieving PD-associated
camptocormia has not been determined. This review introduces the use of DBS in the treatment
of medically refractory camptocormia in patients with PD.
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Figure 1. A patient having PD-associated camptocormia in the standing (A) and recumbent (B) positions.
2. Definition and diagnosis
Camptocormia was first described by Earle (1815) and Brodie (1818). Camptocormia, which is
also referred to as “bent spine syndrome”, was initially considered, especially in war times, to
be a psychogenic disorder and a conversion reaction to war stress (Karbowski, 1999). Camp‐
tocormia is associated with various etiologies, including parkinsonian syndromes, dystonia,
vascular lenticular lesions, and muscular and rheumatologic disorders. It was first described
in association with PD by Djaldetti et al. (1999).
The term camptocormia is now used to describe marked forward flexion of the thoracolum‐
bar spine that varies between 30 and 90 degrees, presents in a sitting position and typically
increases during walking, and completely disappears in the recumbent position, but there
are no criteria with a clear consensus for diagnosing camptocormia. Most of the diagno‐
ses are made by subjectively assessing the patient’s posture. Diagnosing camptocormia in
PD patients  is  based on clinical  examination alone.  Nevertheless,  some specific  findings
might  suggest  alternative  diagnoses.  For  example,  weakness  of  the  truncal  extension
suggests concomitant myopathy or anterior horn cell  disease.  In addition, camptocormia
can  occur  in  other  parkinsonian  syndromes,  such  as  multisystem  atrophy,  progressive
supranuclear  palsy,  or  corticobasal  degeneration.  Patients  with  psychogenic  disorders
sometimes develop movement disorders due to conversion syndromes or malingering. Bent
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spine that is due to simple kyphosis that is associated with degenerative vertebral spinal
changes is easily ruled out, as this phenomenon remains largely unchanged when the patient
is in the recumbent position.
3. Epidemiology
Among the 16 patients with camptocormia that have been described by Azher & Jankovic
2005, the most frequent etiology is PD. The reported prevalence of camptocormia in PD varies
widely. Four studies have described the prevalence rates of camptocormia in patients with PD
as being between 3% and 6-17% (Ashour & Jankovic, 2006; Lepoutre et al., 2006; Tiple et al.,
2009; Abe et al., 2010). This wide range probably reflects the different thresholds that have
been used for diagnosing camptocormia, the lack of a clear definition, and the different
populations that have been studied. Most epidemiological studies show a positive association
between camptocormia and disease severity (Ashour & Jankovic, 2006; Bloch et al., 2006; Tiple
et al., 2009; Margraf et al., 2010), the male gender, older age, longer disease duration, prominent
axial involvement, motor fluctuations, and autonomic symptoms (Lepoutre et al., 2006). In
addition, camptocormia is associated with a high prevalence of lumbar or thoracolumbar
scoliosis (in 61% of the patients) and mild to moderate low-back pain (in 77% of the patients).
On average, camptocormia presents 7–8 years after the onset of parkinsonism in PD (Azher &
Jankovic, Djaldetti et al., 1999; Bloch et al., 2006; Lepoutre et al., 2006; Margraf et al., 2010;
Spuler et al., 2010).
4. Clinical features
Camptocormia occurs mostly in patients with PD in more advanced stages of disease pro‐
gression, but, in a few cases, it appears even in the early stage (Melamed & Djaldetti, 2006). In
some patients, the onset is subacute with the development of significant flexion over days to
months (Lepoutre et al., 2006: Margraf et al., 2010; Spuler et al., 2010). In the majority of patients
with camptocormia, the initial symptoms of PD are bradykinesia and rigidity and, less
frequently, tremor. In almost all patients, the initial signs and symptoms are predominantly
asymmetrical (Melamed & Djaldetti, 2006). The truncal forward flexion is more prominent
when standing (see Fig. 1A) and walking, but complete straightening of the back in the
recumbent position (see Fig. 1B). Normally, the strength in the abdominal and paravertebral
muscles is normal. Some patients can, upon external command or strong self-will, straighten
themselves up, but only for very short periods and at the expense of severe fatigue (Melamed
& Djaldetti, 2006). In quite a number of cases, camptocormia is associated with lower back pain
(Bloch et al., 2006; Lepoutre et al., 2006; Margraf et al., 2010), but, in others, it is painless
(Melamed & Djaldetti, 2006). Some patients report a feeling of being pulled forward or a
sensation of tightening in their abdomen (Azher & Jankovic, 2005). If the deformity is long
established with secondary fixed changes, patients might complain of breathlessness due to
restricted lung capacity or of difficulty lying flat in bed due to hip or knee contractures; the
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latter can be accompanied by skin irritation in the flexed segment (Bloch et al., 2006). Neuro‐
logical examination often reveals marked axial rigidity (Bloch et al., 2006; Lepoutre et al.,
2006). The strength of the trunk and hip extension are normal unless testing is precluded by
fixed posture or pain (Lepoutre et al., 2006). The paraspinal muscles can have a wooden
consistency, and the rectus abdominis often feels tense (Azher & Jankovic, 2005). There might
be compensatory hyperextension of the neck in order to obtain a normal visual field. There is
often mixed deformity, with deviation also in the coronal plane.
5. Pathogenesis of camptocormia in PD
The pathophysiology of the axial postural abnormalities in PD is not well understood, and it
seems to be heterogeneous. However, two possible causes for the camptocormia genesis in
patients with PD have been proposed: dystonia and myopathy.
5.1. Dystonia
Axial or action dystonia is considered a possible etiology of camptocormia in patients with PD
(Ponfick et al., 2011). The first report on camptocormia in PD patients has suggested that bent
spine might represent an action dystonia resulting from dysfunction of the striatum (Djaldetti
et al., 1999). Sławek et al. (2003) have described a PD patient who showed painful camptocor‐
mia that improved markedly after an unilateral pallidotomy, and the findings that DBS has a
beneficial effect on camptocormia support a dystonic etiology (Micheli et al., 2005; Thani et al.,
2011). Another study on camptocormia that was associated with lenticular lesions has also
reported the critical role of the striatum and pallidum in the maintenance of axial posture
(Nieves et al., 2001). Thus, it is possible that PD-associated camptocormia may serve as an axial
dystonia, a result of dysfunction of the basal ganglia controlling the reticulospinal pathway
that projects to the axial muscles (Djaldetti et al., 1999; Nieves et al., 2001; Azher & Jankovic,
2005; Bloch et al., 2006; Melamed & Djaldetti, 2006).
5.2. Myopathy
Recent studies have shown detailed evidence for camptocormia that is caused by a myopathy
of the paraspinal muscles. Gdynia et al. (2009) have investigated paraspinal muscle biopsies
in 19 patients with PD who presented with camptocormia or dropped head syndrome. Thirteen
patients showed myopathic changes in electromyography recordings, and magnetic resonance
imaging showed slight fatty degeneration of the erector spine musculature in three patients.
Histopathological analyses of the patients with PD have demonstrated a wide spectrum of
abnormalities in the skeletal muscles of those with camptocormia and dropped head syn‐
drome. Spuler et al. (2010) have examined 17 patients, 13 of whom had a myopathic pattern
in electromyographic recordings. The authors found apparently folded proteins in the muscle
biopsies, suggesting the possibility of a myopathy that was induced by an accumulation of
aggregated proteins. Margraf et al. (2010) have examined 15 patients with PD and campto‐
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cormia with electromyography, muscle magnetic resonance imaging, and biopsy of the
paravertebral muscles. They showed increased levels of creatine kinase in 9/15 patients,
myogenic electromyographic changes in 8/15 patients, and myopathic changes in the muscle
biopsies in 12/15 patients. They claimed that the cause of camptocormia in idiopathic PD is a
focal myopathy and that the myopathy has a progressive course, resulting in degeneration of
the paravertebral muscles.
6. Treatment
6.1. Pharmacotherapy
In the majority of cases with advanced PD, camptocormia is thought to be unresponsive to
levodopa (Azher & Jankovic, 2005; Margraf et al., 2010). Depending on the investigated cohort,
up to 20% of the patients with PD and camptocormia profit from levodopa therapy (Bloch et
al., 2006). The adjustment of dopaminergic therapy by carbidopa-levodopa and entacapone
has been shown to result in improvements in camptocormia. Fujimoto (2006) has described
the deterioration of camptocormia in patients who were treated with dopamine agonists, thus
suggesting that the withdrawal of these agents might lead to an improvement of camptocormia
in some cases. The poor responses to these medical agents can be explained by the fact that,
when postural abnormalities and postural instabilities appear, patients are already at an
advanced stage of the disease with severe axial symptoms, and all of their symptoms are
known to respond poorly to levodopa, suggesting the involvement of non-dopaminergic
pathways (Campbell et al., 2003). Furthermore, postural reactions that support surface
perturbations are resistant to dopaminergic therapy (Carpenter et al., 2004).
In patients who seem to have a predominantly dystonic element, another treatment option
might be botulinum toxin injections in the rectus abdominis muscles (Azher & Jankovic,
2005; Jankovic, 2009; Bonanni et al., 2007; Lenoir et al., 2010). Azher and Jankovic (2005) have
found this to be successful in selected patients, but few have reproduced their positive results.
6.2. Spinal surgery
Spinal surgery has been used to attenuate postural abnormalities in patients with camptocor‐
mia associated with PD, whereas it has significant complications, and often requires revision
surgery (Babat et al., 2004; Peek et al., 2009; Koller et al., 2010; Wadia et al., 2011).
6.3. DBS
Stereotactic neurosurgery of the basal ganglia is a therapeutic alternative for patients with
advanced PD. As DBS of the STN or GPi produces a significant improvement in the motor
symptoms in patients with severe PD, it also can be effective in treating camptocormia
associated with PD (see Table 1.).
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DBS target author/year No ofpatients age
duration of PD
(years) Improvement
follow up
(months)
STN Azher and JanKovic(2005) 1 n.a. n.a. 0/1 n.a.
Hellman et al. (2006) 1 53 25 1/1 10
Yamada et al. (2006) 1 71 11 1/1 20
Sako et al. (2009) 6 53-71 5-11 6/6 5-46
Capelle et al (2010) 2 73/65 12/15 1/2 12-16
Umemura et al. (2010) 8 59-79 8-20 6/8 12
Upadhyaya et al (2010) 1 59 n.a. 0/1 2
Asahi et al. (2011) 4 60-69 7-13 3/4 40
Lyons et al. (2012) 1 63 19 1/1 3
GPi Micheli et al. (2005) 1 62 10 1/1 14
Upadhyaya et al. (2010) 1 59 n.a. 0/1 15
Capelle et al. (2010) 1 64 10 1/1 36
Thani et al. (2011) 1 57 13 1/1 14
n.a. = not applicable
Table 1. DBS for camptocormia: literature review
6.3.1. STN-DBS
STN-DBS is thought to be superior to GPi-DBS in improving the cardinal motor symptoms of
PD and in reducing the dosage of dopaminergic medications in PD patients (Moro et al.,
1999; Deep-Brain Stimulation for Parkinson's Disease Study Group, 2001; Krack et al., 2003).
As far as we are aware, 25 patients in 9 reports have been reported as having undergone STN-
DBS for PD with camptocormia, and 19 of the patients (76%) showed improvements of the
camptocormia. Sako et al. (2009) have described 6 PD patients with severe camptocormia who
underwent bilateral STN-DBS. In this series, improvements of the camptocormia were
reported in all of the patients after STN-DBS (see Fig. 2). Improvement was defined as a change
in the thoracolumbar angle that was sustained for a mean follow-up period of 17 months.
Umemura et al. (2010) and Capelle et al. (2011) have shown a positive effect of STN-DBS on
PD-associated camptocormia, but not in all of the patients. In their studies, only the severity
of the postural abnormality was shown to be related to improvements in the postural abnor‐
malities after STN-DBS; moderate, rather than severe, postural abnormalities tended to
improve after surgery (Umemura et al., 2010; Capelle et al., 2011). Asahi et al. (2011) have
described 4 cases with advanced PD with camptocormia that were treated with STN-DBS, with
improvements of the camptocormia in 3 patients but no improvement in one patient. In their
computed tomography study, the single patient who did not show improvement of the
camptocormia exhibited marked muscle atrophy and degeneration of the fatty tissue in her
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paraspinal muscle (Asahi et al., 2011). Thus, STN-DBS is a potential treatment for camptocor‐
mia in patients with PD, but the outcomes have varied from excellent improvement to only
mild improvement or no benefit. Camptocormia usually does not respond to levodopa
treatment and STN-DBS is thought to be effective mainly for the dopa-responsive PD symp‐
toms. The mechanisms by which STN-DBS improves camptocormia in some patients and not
in others remain unclear. As the recent reports that have shown the beneficial effects of STN-
DBS in the treatment of primary dystonias (Kleiner-Fisman et al., 2007; Novak et al., 2008;
Ostrem et al., 2011; Fonoff et al., 2012), axial posturing could be controlled by the STN as a
function of the basal ganglia.
(A) Preoperative state; (B) Postoperative state
Figure 2. An impact of STN-DBS on camptocormia in a patient with PD.
6.3.2. GPi-DBS
The GPi is an alternative target that can be considered in the treatment of camptocormia.
Previous research on patients with PD and camptocormia that was treated with GPi-DBS is
limited to only four cases, with reports of no improvement in posture in one and improvement
in posture in three (Micheli et al., 2005; Upadhyaya et al., 2010; Capelle et al., 2011; Thani et
al., 2011). If camptocormia is considered a form of dystonia, then it is not surprising that high-
frequency DBS of the GPi results in improvements because there is a large body of evidence
of a dramatic effect of pallidal surgery on various forms of dystonia (for a review see Vidailhet
et al., 2013). Micheli et al. (2005) have described a PD patient in whom bilateral GPi-DBS
showed beneficial and sustained improvement of the PD symptoms and improvement of the
camptocormia six months after surgery. In addition, Thani et al. (2011) have reported slow but
steady improvement of camptocormia by six months, which was sustained at 14 months, after
GPi-DBS in patients with PD. This progressive resolution of symptoms is reminiscent of the
response that is expected in other forms of dystonia, with optimal improvement often requiring
months.
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7. Conclusion
Reports of success in controlling axial posturing in patients with camptocormia with both STN
and GPi stimulation support the notion that the basal ganglia plays an important role in the
maintenance of posture. Although both STN-DBS and GPi-DBS can be potential surgical means
for treating camptocormia in patients with PD, further studies need to be performed in order
to confirm this conclusion and to select PD patients with medically refractory camptocormia
who are optimal candidates for STN or GPi DBS.
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